缺陷的DNA损伤反应是ESR1突变乳腺癌中可向的治疗脆弱性
Sarah K Herzog1, Jessica H Stevens2, Guowei Gu1
1Baylor College of Medicine Houston, TX United States.
Cancer research
|January 7, 2026
概括
雌激素受体1 (ESR1) 突变在转移性乳腺癌中驱动对内分泌治疗的耐药性. 用PARP抑制剂向DNA损伤反应显示出治疗这种耐药癌症亚群的前景.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 雌激素受体1 (ESR1) 突变是ER阳性转移性乳腺癌内分泌治疗耐药性和疾病进展的主要驱动因素.
- 大约50%的转移性乳腺癌患者携带ESR1突变,需要开发新的向疗法.
研究的目的:
- 研究复制应激和DNA损伤反应在ESR1-突变乳腺癌中的作用.
- 评估针对ESR1突变转移性乳腺癌中这些途径的治疗潜力,特别是PARP抑制剂.
主要方法:
- 对ESR1突变模型的分析,以确定失调的途径.
- 结合检查点抑制剂与PARP抑制剂的体外和体内研究.
- 对Olaparib捕获PARP的评估及其与ER-PARP的相互作用1.
- 评估abemaciclib诱导的ESR1突变和随后的途径反应.
- 用PARP抑制剂和内分泌治疗进行组合治疗的研究.
主要成果:
- 在ESR1突变模型中,表现出失调的复制应激和DNA损伤反应的丰富.
- 结合检查点和PARP抑制可以协同抑制瘤生长,诱导细胞循环停止和减少DNA复制.
- 抑制PARP阻断了转移性传播,并降低了PARP1和ER蛋白的表达.
- 在ESR1突变细胞中,olaparib治疗增加了同局部DNA结合的PARP1和ER蛋白.
- 在abemaciclib治疗下出现Y537S ESR1突变导致复制应激反应失调和对途径抑制剂的协同反应.
- PARP抑制与内分泌疗法协同作用,减少ESR1突变模型中的瘤生长.
结论:
- 复制应激和DNA损伤反应是ESR1-突变乳腺癌中关键的失调途径.
- 抑制PARP显示出作为这种转移性乳腺癌子组的向治疗的显著临床潜力.
- 了解ESR1突变细胞中的ER-PARP1共同调节提供了新的治疗见解.
相关概念视频
Nucleotide Excision Repair
5.0K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
5.0K
Nucleotide Excision Repair
40.6K
Overview
40.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Base Excision Repair
25.9K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
The first step of...
25.9K
DNA Damage can Stall the Cell Cycle
10.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.0K


